BBLG - Bone Biologics Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2009
+0.0169 (+9.18%)
As of 02:20PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.1840
Open0.1870
Bid0.1910 x 1800
Ask0.2000 x 800
Day's Range0.1770 - 0.2100
52 Week Range0.1400 - 1.9700
Volume340,812
Avg. Volume572,012
Market Cap3.356M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.3300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BBLG

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zacks Small Cap Research

    BBLG: BBLG Has Solid Cash and Is Advancing Testing

    By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) recently announced that it has received approval to begin pilot clinical trials with NB1 in spinal fusion patients. The approval was given by the Human Research Ethics Committee and the trials will take place in Australia. This is an important and exciting step for Bone as the study will evaluate the

  • Zacks Small Cap Research

    BBLG: Bone Biologics Announces the Approval of A Vital Trial

    By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced that it has received approval to begin pilot clinical trials with NB1 in spinal fusion patients. The approval was given by the Human Research Ethics Committee and the trials will take place in Australia. This is an important and exciting step for Bone as the study will evaluate the safety

  • Business Wire

    Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

    BURLINGTON, Mass., April 11, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia.

  • Zacks Small Cap Research

    BBLG: BBLG Provides Investment Opportunity Before Trials

    By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) continues to be a company that we are excited about as it pursues a way to improve the outcomes of spinal fusion surgery, while also having the potential to impact trauma and osteoporosis applications in a positive way. The Nell-1 technology is about to enter human clinical trials and recently

  • Business Wire

    Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

    BURLINGTON, Mass., January 26, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1. Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology and drug-device combination products. The trial will evaluate the safety and effectiveness of Bone Biologic’s novel NB

  • Zacks Small Cap Research

    BBLG: A Potential Game-Changer for Back Surgeries

    By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a medical device company focused on addressing the spinal fusion market with their worldwide exclusive use of the NELL-1 technology developed by the UCLA Technology Development Group (UCLA TDG). NELL-1 has shown in clinical studies involving rats the ability to stimulate bone growth in a more

  • Business Wire

    Bone Biologics CEO Issues Letter to Stockholders

    BURLINGTON, Mass., October 25, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.

  • PR Newswire

    WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering

    WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services announced yesterday the closing of Bone Biologics (NASDAQ: BBLG) previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

  • Business Wire

    Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering

    BURLINGTON, Mass., October 12, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company plans to use the net proceeds to fund its planned clinical trials, maintain and extend its patent por

  • Business Wire

    CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering

    BURLINGTON, Mass., October 07, 2022--Reissuing release to remove "million" after "$5,100,000" in the headline and first sentence of the text.

  • PR Newswire

    WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering

    WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion, announced the pricing of an underwritten public offering of 3,777,778 units at an offering price of $1.35 per unit, for total gross proceeds of $5,100,000 before deducting underwriting discounts and commissions and other offering expenses.

  • Zacks Small Cap Research

    BBLG: Market opportunity for Bone continues to grow.

    By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a company advancing a technology, known as NELL-1, that could positively impact millions of Americans suffering with back pain, and stands to be in the middle of the increasing demand for treatment of such conditions as osteoporosis, which is estimated to be valued at $14 billion by Coherent

  • Zacks Small Cap Research

    BBLG: Bone Biologics Set up For Success

    By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Although the stock (NASDAQ:BBLG) of Bone Biologics has suffered along with the rest of the biotech-related space, we remain confident in the company’s technology to improve the bone regeneration process, potentially providing relief to millions of back pain sufferers in the US and around the world. The NELL-1 protein and the way